Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice.

MERS-CoV SARS-CoV SARS-CoV-2 bat coronavirus nanoparticle neutralization receptor binding domain universal vaccine

Journal

bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187

Informations de publication

Date de publication:
23 May 2023
Historique:
pubmed: 9 6 2023
medline: 9 6 2023
entrez: 9 6 2023
Statut: epublish

Résumé

The emergence of three distinct highly pathogenic human coronaviruses - SARS-CoV in 2003, MERS-CoV in 2012, and SARS-CoV-2 in 2019 - underlines the need to develop broadly active vaccines against the

Identifiants

DOI: 10.1101/2023.05.22.540829 PMID: 37293083 PMC: PMC10245799
pubmed: 37293083
doi: 10.1101/2023.05.22.540829
pmc: PMC10245799
pii:
doi:

Types de publication

Preprint

Langues

eng

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI158571
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA260543
Pays : United States

Commentaires et corrections

Type : UpdateIn

Déclaration de conflit d'intérêts

Competing interests: B.F.H. and K.O.S. have filed US patents regarding the nanoparticle vaccine. R.S.B. is on the scientific advisory boards of VaxArt, Invivyd, and Takeda.

Auteurs

David R Martinez (DR)

Department of Immunobiology, Yale School of Medicine, New Haven, CT, 06510, USA.
Yale Center for Infection and Immunity, Yale School of Medicine, New Haven, CT, 06510, USA.

Alexandra Schafer (A)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Tyler D Gavitt (TD)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Michael L Mallory (ML)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Esther Lee (E)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Nicholas J Catanzaro (NJ)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Haiyan Chen (H)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Kendra Gully (K)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Trevor Scobey (T)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Pooja Korategere (P)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Alecia Brown (A)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Lena Smith (L)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Rob Parks (R)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Maggie Barr (M)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Amanda Newman (A)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Cindy Bowman (C)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

John M Powers (JM)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Katayoun Mansouri (K)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Robert J Edwards (RJ)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Ralph S Baric (RS)

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.

Barton F Haynes (BF)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Kevin O Saunders (KO)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.

Classifications MeSH